Science Explorer Back to mapMap
Institution · Galapagos (France)

Most cited papers from Galapagos (France)

What are the most cited papers from Galapagos (France)?

The most cited paper from Galapagos (France) is "Targeting the Wnt/β-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton" (Roland Baron, Georges Rawadi, 2007), with 587 citations. Next come "JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib" (359) and "Anti‐rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen‐induced arthritis in rodents" (275).

Showing 50 of 60 papers. Every paper with more than 31 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Targeting the Wnt/β-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton Roland Baron, Georges Rawadi · Endocrinology 30 Mar 2007 587
2 JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib Paqui G. Través, Bernard P. Murray, Federico Campigotto et al. · Annals of the Rheumatic Diseases Open access 19 Mar 2021 359
3 Anti‐rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen‐induced arthritis in rodents H‐S Lin, Ching Yuan Hu, H‐Y Chan et al. · British Journal of Pharmacology Open access 26 Feb 2007 275
4 Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial Toby M. Maher, Ellen M. van der Aar, Olivier Van de Steen et al. · The Lancet Respiratory Medicine Open access 20 May 2018 238
5 Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases Luc Van Rompaey, René Galien, Ellen M. van der Aar et al. · The Journal of Immunology Open access 5 Sep 2013 237
6 Tumor αvβ3 Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases Yingshe Zhao, Richard Bachelier, Isabelle Treilleux et al. · Cancer Research 15 Jun 2007 211
7 A pan-serotype dengue virus inhibitor targeting the NS3–NS4B interaction Suzanne J. F. Kaptein et al. · Nature Open access 6 Oct 2021 202
8 Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2- a ]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis Nicolas Desroy et al. · Journal of Medicinal Chemistry Open access 17 Apr 2017 141
9 Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis Toby M. Maher et al. · JAMA Open access252 authors 9 May 2023 140
10 Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection Florence Namour, Paul M. Diderichsen, Eugene H. Cox et al. · Clinical Pharmacokinetics Open access 13 Feb 2015 138
11 Blocking NS3–NS4B interaction inhibits dengue virus in non-human primates Olivia Goethals et al. · Nature Open access 15 Mar 2023 136
12 Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634 Christel J. Menet, Stephen Robert Fletcher, Guy Van Lommen et al. · Journal of Medicinal Chemistry Open access 4 Nov 2014 124
13 Neutralization of IL-17C Reduces Skin Inflammation in Mouse Models of Psoriasis and Atopic Dermatitis Nick Vandeghinste, Jürgen Klattig, Catherine Jagerschmidt et al. · Journal of Investigative Dermatology Open access 21 Feb 2018 118
14 The Hedgehog Receptor Patched Is Involved in Cholesterol Transport Michel Bidet, Olivier Joubert, Benoı̂t Lacombe et al. · PLoS ONE Open access 8 Sep 2011 117
15 Discovery and Optimization of an Azetidine Chemical Series As a Free Fatty Acid Receptor 2 (FFA2) Antagonist: From Hit to Clinic Mathieu Pizzonero et al. · Journal of Medicinal Chemistry Open access 7 Nov 2014 114
16 Targeted Disruption of the Wnt Regulator Kremen Induces Limb Defects and High Bone Density Kristina Ellwanger, Hiroaki Saito, Philippe Clément-Lacroix et al. · Molecular and Cellular Biology Open access 28 May 2008 108
17 Targeting of αv-Integrins in Stem/Progenitor Cells and Supportive Microenvironment Impairs Bone Metastasis in Human Prostate Cancer Geertje van der Horst, Christel van den Hoogen, Jeroen T. Buijs et al. · Neoplasia Open access Jun 2011 108
18 The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis Tobias Puengel, Steve De Vos, Jana Hundertmark et al. · Journal of Clinical Medicine Open access 16 Apr 2020 87
19 Ex vivo tissue perturbations coupled to single-cell RNA-seq reveal multilineage cell circuit dynamics in human lung fibrogenesis Niklas Jonathan Lang et al. · Science Translational Medicine 6 Dec 2023 85
20 Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials Frédéric P. Vanhoutte, Minodora Mazur, O.I. Voloshyn et al. · Arthritis & Rheumatology Open access 16 Jun 2017 82
21 Discovery of Diarylhydantoins as New Selective Androgen Receptor Modulators François Nique, Séverine Hebbe, Christophe Peixoto et al. · Journal of Medicinal Chemistry Open access 16 Aug 2012 79
22 Advances in the Discovery of Selective JAK Inhibitors Christel J. Menet, Luc Van Rompaey, Raphaël Geney · Progress in medicinal chemistry Book chapter 2013 78
23 No evidence for a bone phenotype in GPRC6A knockout mice under normal physiological conditions Petrine Wellendorph, Lars Dan Johansen, Anders A. Jensen et al. · Journal of Molecular Endocrinology Open access 22 Dec 2008 73
24 Envisioning the Future of European Food Systems: Approaches and Research Priorities After COVID-19 Matteo Vittuari et al. · Frontiers in Sustainable Food Systems Open access 9 Mar 2021 65
25 A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies Geert A. Cirkel, Bojana Milojkovic Kerklaan, Frédéric P. Vanhoutte et al. · Investigational New Drugs Open access 19 Jan 2016 65
26 Discovery, Structure–Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors Agnès Joncour et al. · Journal of Medicinal Chemistry Open access 21 Jul 2017 63
27 BMP-7 inhibits TGF-β-induced invasion of breast cancer cells through inhibition of integrin β3 expression Hildegonda P. H. Naber, Eliza Wiercinska, Evangelia Pardali et al. · Cellular Oncology Open access 20 Sep 2011 62
28 Filgotinib: A Clinical Pharmacology Review Florence Namour, Kacey Anderson, Cara Nelson et al. · Clinical Pharmacokinetics Open access 31 May 2022 60
29 Discovery of GLPG1972/S201086, a Potent, Selective, and Orally Bioavailable ADAMTS-5 Inhibitor for the Treatment of Osteoarthritis F. Brebion et al. · Journal of Medicinal Chemistry Open access 15 Mar 2021 60
30 Discovery ofN-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-lH-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High Extent Steven E. Van der Plas, Hans Kelgtermans, Tom De Munck et al. · Journal of Medicinal Chemistry Open access 17 Nov 2017 59
31 Shedding Light on Important Waters for Drug Design: Simulations versus Grid-Based Methods Denis Bucher, Pieter F. W. Stouten, Nicolas Triballeau · Journal of Chemical Information and Modeling 28 Feb 2018 58
32 Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects Florence Namour, René Galien, Tim Van Kaem et al. · British Journal of Clinical Pharmacology Open access 8 Feb 2016 57
33 Genetic depletion and pharmacological targeting of αv integrin in breast cancer cells impairs metastasis in zebrafish and mouse xenograft models Yihao Li, Yvette Drabsch, Philippe Pujuguet et al. · Breast Cancer Research Open access 24 Feb 2015 57
34 Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions Florence Namour, Julie Desrivot, Annegret Van der Aa et al. · Drug Metabolism Letters 12 Feb 2016 56
35 Adenomatous polyposis coli-mediated control of β-catenin is essential for both chondrogenic and osteogenic differentiation of skeletal precursors Razvan L. Miclea, Marcel Karperien, Cathy A.J. Bosch et al. · BMC Developmental Biology Open access 8 Apr 2009 56
36 GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy Anna Cozzoli, Roberta Francesca Capogrosso, Valeriana Teresa Sblendorio et al. · Pharmacological Research 22 Mar 2013 56
37 Inhibition of Autotaxin with GLPG1690 Increases the Efficacy of Radiotherapy and Chemotherapy in a Mouse Model of Breast Cancer Xiaoyun Tang, Melinda Wuest, Matthew G.K. Benesch et al. · Molecular Cancer Therapeutics 23 Sep 2019 54
38 Identification of a 4-(Hydroxymethyl)diarylhydantoin as a Selective Androgen Receptor Modulator François Nique, Séverine Hebbe, Nicolas Triballeau et al. · Journal of Medicinal Chemistry 10 Sep 2012 53
39 IL‐17C amplifies epithelial inflammation in human psoriasis and atopic eczema Felix Lauffer, Manja Jargosch, Veronika Baghin et al. · Journal of the European Academy of Dermatology and Venereology Open access 2 Dec 2019 52
40 Three classes of ligands each bind to distinct sites on the orphan G protein-coupled receptor GPR84 Zobaer Al Mahmud, Laura Jenkins, Trond Ulven et al. · Scientific Reports Open access 14 Dec 2017 50
41 Small molecule inhibitors of IκB kinase signaling inhibit osteoclast formation in vitro and prevent ovariectomy‐induced bone loss in vivo Aymen I. Idris, Maala Krishnan, Petra Šimić et al. · The FASEB Journal 20 Jul 2010 49
42 Discovery of 9-Cyclopropylethynyl-2-(( S )-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1- a ]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial Frédéric Labéguère et al. · Journal of Medicinal Chemistry Open access 9 Sep 2020 48
43 IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases Stéphanie Lavazais, Manja Jargosch, Sonia Dupont et al. · Science Translational Medicine 15 Feb 2023 44
44 Identification of GLPG/ABBV-2737, a Novel Class of Corrector, Which Exerts Functional Synergy With Other CFTR Modulators Gert De Wilde, Maarten Gees, Sara Musch et al. · Frontiers in Pharmacology Open access 9 May 2019 42
45 Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials Ellen van der Aar, Julie Desrivot, Sonia Dupont et al. · The Journal of Clinical Pharmacology Open access 23 Apr 2019 42
46 Targeting of Alpha-V Integrins Reduces Malignancy of Bladder Carcinoma Geertje van der Horst, Lieke Bos, Maaike van der Mark et al. · PLoS ONE Open access 23 Sep 2014 42
47 Hydrogen sulphide‐releasing diclofenac derivatives inhibit breast cancer‐induced osteoclastogenesis in vitro and prevent osteolysis ex vivo Joseph Frantzias, John G. Logan, Patrick Mollat et al. · British Journal of Pharmacology Open access 28 Sep 2011 42
48 Autotaxin facilitates selective LPA receptor signaling Fernando Salgado-Polo, Razvan Borza, Minos–Timotheos Matsoukas et al. · Cell chemical biology Open access 2023 41
49 Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials Jacqueline M. Tarrant, René Galien, Wanying Li et al. · Rheumatology and Therapy Open access 7 Jan 2020 37
50 Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells Francesca Megiorni et al. · Journal of Hematology & Oncology Open access 6 Oct 2017 37

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.